https://seekingalpha.com/article/4765289-ocular-therapeutix-axpaxlis-dual-trial-strategy-and-blockbuster-potential [Seeking Alpha]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Seeking Alpha
Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026. OCUL is also working on expanding Axpaxli's indications into NPDR/DME to tap a vast, largely untreated diabetic retinopathy market. In my view, the recent pullback makes OCUL a great speculative “Strong Buy” due to its large aggregate TAM and clear regulatory pathway at this stage. megaflopp Ocular Therapeutix Overview Ocular Therapeutix ( NASDAQ: OCUL ) is a biotech working on treatments for retinal diseases. Since my June 2024 article on them, the company has focused on its flagship drug candidate called “Axpaxli.” For context
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix, Inc. (NASDAQ: OCUL) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- Ocular Therapeutix, Inc. (NASDAQ: OCUL) was given a new $19.00 price target on by analysts at JMP Securities.MarketBeat
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Ocular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026 [Seeking Alpha]Seeking Alpha
OCUL
Earnings
- 3/3/25 - Miss
OCUL
Sec Filings
- 3/3/25 - Form 10-K
- 3/3/25 - Form 8-K
- 2/26/25 - Form 4
- OCUL's page on the SEC website